* Puma Biotechnology Inc PBYI.OQ PBYI.O is expected
to show a
fall in quarterly revenue when it reports results on May 5.
* The Los Angeles California-based company is expected to
report
a 54.1% decrease in revenue to $45.067 million from $98.17
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Puma Biotechnology
Inc is
for a loss of 17 cents per share. For the same quarter last
year, the company reported earnings of 40 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and 3 "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 15.0%
in the last three months.
* Wall Street's median 12-month price target for Puma
Biotechnology Inc is $5, above its last closing price
of $2.40.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.08 -0.09 0.10 Beat 214.2
Sep. 30 2021 -0.32 -0.31 -0.90 Missed -188.8
Jun. 30 2021 -0.25 -0.27 -0.13 Beat 52.1
Mar. 31 2021 0.16 0.09 0.40 Beat 359.8
Dec. -0.41 -0.31 -0.38 Missed -21.7
31 2020
Sep. 30 2020 -0.41 -0.39 -0.79 Missed -100.1
Jun. 30 2020 -0.34 -0.30 0.08 Beat 126.9
Mar. 31 2020 -0.78 -0.77 -0.43 Beat 44.3
This summary was machine generated May 4 at 02:09 GMT. All
figures in US dollars unless otherwise stated